To no one's surprise, Mark McClellan, MD, announced last month that he would leave his job as administrator of the Centers for Medicare and Medicaid Services (CMS) after six years with the Bush Administration.
To no one's surprise, Mark McClellan, MD, announced last month that he would leave his job as administrator of the Centers for Medicare and Medicaid Services (CMS) after six years with the Bush Administration.
This change in leadership comes at a critical time politically.
Although Medicare Part D is up and running and important reforms in Medicaid are in the works, access to affordable healthcare and prescription drugs will be a hot issue in the November Congressional elections and the 2008 presidential campaign. Republicans will want to tout their accomplishments, while Democrats will highlight problems and claim they can do better.
The managed care community applauded his support of private plans in delivering quality care.
CHALLENGES AHEAD
As CMS officials head into a much shorter open enrollment season (only six weeks) for the Medicare drug benefit and for Medicare Advantage plans, they face some of the same challenges that emerged last year:
At the same time, CMS confirmed that Part B premiums will rise 5.6% to $93.50 a month-less than expected, but still a hefty amount. Deductibles and copays for seniors needing hospitalization also will go up, amounting to thousands of dollars for long hospitals stays.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More